BetterLife Pharma Inc. (GETTEX:NPAU) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Public offering of common shares and pre-funded warrants Closed: US$100M raised · C$0.25 a share · Bloom Burton Securities Inc. +1 Dealers: Bloom Burton Securities Inc. (lead), Haywood Securities Inc. Buyers: Deep Track Capital (led the financing); Coastlands Capital (significant co-investment); Marshall Wace (significant co-investment); RA Capital Management (significant co-investment); Perceptive Advisors (significant co-investment); Adage Capital Management (participation); Affinity Asset Advisors (participation); Kalehua Capital (participation); Sphera Fund Management (participation); Squadron Capital Management (participation); Stonepine Capital Management (participation); Woodline Partners LP (participation) Use of proceeds: Phase 1A, Phase 1B and Phase 2 clinical trials of BETR-001 in cluster headache and migraine, plus working capital and general corporate purposes | Sep 17, 2026 | |
| Convertible debenture Closed: C$2M raised · C$0.06 · 1 warrant at C$0.1 for 36 months Insiders: A director and insider of the Company subscribed for $2,000,000 of the Debenture; conversion subject to a 19.9% ownership cap absent shareholder approval Use of proceeds: Complete remaining IND-enabling activities for BETR-001 and general working capital | Jun 22, 2026 | US$1.41M |
| Warrant exercise of common shares on exercise of share purchase warrants Closed: C$25,000 raised | May 6, 2025 | US$18,138 |